Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio A Emini

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
Vaccine|May 22, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccineLisa A Jackson, Alejandra Gurtman, Kathryn Rice, et al.
The Pediatric Infectious Disease Journal|October 30, 2012
Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccineKristina A Bryant, Alejandra Gurtman, Douglas Girgenti, et al.
Vaccine|May 22, 2013
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and olderLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Vaccine|October 27, 2012
A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in BrazilLily Yin Weckx, Allison Thompson, Eitan Naaman Berezin, et al.
Vaccine|February 21, 2015
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccinationJacek Wysocki, Jerzy Brzostek, Henryk Szymański, et al.
The Pediatric Infectious Disease Journal|October 19, 2013
13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccineRobert Frenck, Allison Thompson, Shelly Senders, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2002
Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'Subharekha Raghavan, Zheng Yang, Ralph T Mosley, et al.
The Pediatric Infectious Disease Journal|February 4, 2012
13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safetyFederico Martinón-Torres, Francisco Gimenez-Sanchez, Alejandra Gurtman, et al.
Clinical and Vaccine Immunology : CVI|June 29, 2012
Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adultsRobert W Frenck, Alejandra Gurtman, John Rubino, et al.
Vaccine|February 22, 2011
Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccineJanusz Gadzinowski, Piotr Albrecht, Barbara Hasiec, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Vaccine|May 22, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccineLisa A Jackson, Alejandra Gurtman, Kathryn Rice, et al.
The Pediatric Infectious Disease Journal|October 30, 2012
Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccineKristina A Bryant, Alejandra Gurtman, Douglas Girgenti, et al.
Vaccine|May 22, 2013
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and olderLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Vaccine|October 27, 2012
A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in BrazilLily Yin Weckx, Allison Thompson, Eitan Naaman Berezin, et al.
Vaccine|February 21, 2015
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccinationJacek Wysocki, Jerzy Brzostek, Henryk Szymański, et al.
The Pediatric Infectious Disease Journal|October 19, 2013
13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccineRobert Frenck, Allison Thompson, Shelly Senders, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2002
Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'Subharekha Raghavan, Zheng Yang, Ralph T Mosley, et al.
The Pediatric Infectious Disease Journal|February 4, 2012
13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safetyFederico Martinón-Torres, Francisco Gimenez-Sanchez, Alejandra Gurtman, et al.
Clinical and Vaccine Immunology : CVI|June 29, 2012
Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adultsRobert W Frenck, Alejandra Gurtman, John Rubino, et al.
Vaccine|February 22, 2011
Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccineJanusz Gadzinowski, Piotr Albrecht, Barbara Hasiec, et al.
Pageof 9